Escherichia coli leucyl/phenylalanyl-tRNA protein transferase catalyzes the tRNA-dependent post-translational addition of amino acids onto the N-terminus of a protein polypeptide substrate. Based on biochemical and structural studies, the current tRNA recognition model by L/F transferase involves the identity of the 3' aminoacyl adenosine and the sequence-independent docking of the D-stem of an aminoacyl-tRNA to the positively charged cluster on L/F transferase. However, this model does not explain the isoacceptor preference observed 40 yr ago. Using in vitro-transcribed tRNA and quantitative MALDI-ToF MS enzyme activity assays, we have confirmed that, indeed, there is a strong preference for the most abundant leucyl-tRNA, tRNA(Leu) (anticodon 5'-CAG-3') isoacceptor for L/F transferase activity. We further investigate the molecular mechanism for this preference using hybrid tRNA constructs. We identified two independent sequence elements in the acceptor stem of tRNA(Leu) (CAG)-a G₃:C₇₀ base pair and a set of 4 nt (C₇₂, A₄:U₆₉, C₆₈)-that are important for the optimal binding and catalysis by L/F transferase. This maps a more specific, sequence-dependent tRNA recognition model of L/F transferase than previously proposed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105747 | PMC |
| http://dx.doi.org/10.1261/rna.044529.114 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer.
Cancer Res Commun
January 2025
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
Eliminating "persisters" before relapse is crucial for achieving durable treatment efficacy. This study provides a rationale for developing PRMT1-selective inhibitors to target cancer persisters and achieve more durable outcomes in oncogene-targeting therapies.
View Article and Find Full Text PDFAsymptomatic HyperCKemia in the Pediatric Population: A Prospective Study Utilizing Next-Generation Sequencing and Ancillary Tests.
Neurology
January 2025
From the U763 (P.M., N.M., I.A., T.S., J.J.V.), Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Madrid; Neuromuscular Research Group (P.M., I.P.C., N.M., I.A., L.F., R.V., T.S., J.J.V.), IIS La Fe; Neuromuscular Referral Center ERN-EURO-NMD (I.P.C.), Neuropediatric Department, UIP La Fe Hospital; Neuromuscular Referral Center ERN-EURO-NMD (N.M., T.S.), Neurology Department, UIP La Fe Hospital, Valencia; and Department of Medicine (N.M., T.S., J.J.V.), Universitat de Valencia, Spain.
Article Synopsis
- - The study focuses on diagnosing asymptomatic hyperCKemia in pediatric patients using next-generation sequencing (NGS) and other diagnostic tools, as genetic myopathies are often linked to elevated creatine kinase levels.
- - Conducted on 65 patients, the study found that NGS successfully diagnosed 55% of cases, with seven specific genes frequently showing pathogenic variants, while muscle biopsies were crucial for identifying myopathologic features.
- - The research highlighted the effectiveness of EMG in revealing myopathic features in 48% of cases, although some diagnostic challenges remained, with 14% and 29% of diagnoses being inconclusive.
Improved precision, sensitivity, and adaptability of Ordered Two-Template Relay cDNA library preparation for RNA sequencing.
bioRxiv
November 2024
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, USA.
Article Synopsis
- The Ordered Two-Template Relay (OTTR) method captures complete RNA sequences and appends sequencing adapters in a single reverse transcription step, aiming to improve data yield and reduce bias in sequencing short RNAs.
- Researchers optimized various factors such as reaction buffers, reverse transcriptase sequences, and adapter oligonucleotides to enhance precision in capturing RNA sequences and minimizing overall library bias.
- The updated OTTR protocol also reduces bacterial contamination in sequencing results and includes a rapid, automated process for efficiently enriching cDNA without unwanted byproducts.
Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science.
Clin Transl Sci
November 2024
Morcos Pharmaceutical Consulting, LLC, Marlboro, New Jersey, USA.
Most cancers and neoplastic progenitor cells have elevated telomerase activity and preservation of telomeres that promote cellular immortality, making telomerase a rational target for the treatment of cancer. Imetelstat is a first-in-class, 13-mer oligonucleotide that binds with high affinity to the template region of the RNA component of human telomerase and acts as a competitive inhibitor of human telomerase enzymatic activity. Pharmacokinetics, pharmacodynamics, exposure-response analyses, efficacy, and safety of imetelstat have been evaluated in vitro, in vivo, and clinically in solid tumor and hematologic malignancies, including lower-risk myelodysplastic syndromes (LR-MDS) and myeloproliferative neoplasms.
View Article and Find Full Text PDFThe genomic and transcriptomic landscape of metastastic urothelial cancer.
Nat Commun
October 2024
Department of Genetics, Institut Curie, 75005, Paris, France.
Article Synopsis
- Metastatic urothelial carcinoma (mUC) is a dangerous cancer with few treatment options, and its genetic makeup is not fully understood unlike non-metastatic urothelial carcinoma (UC).
- A study analyzing genetic data from 111 mUC biopsies found that common genetic changes are similar to those seen in primary UC and highlighted mutational signatures related to APOBEC, platinum sensitivity, and homologous recombination deficiency.
- The research revealed that a significant portion of mUC patients have potential therapeutic targets, with the most common being FGFR3, ERBB2, TSC1, and PIK3CA, and noted that certain genes like NECTIN4 and TACSTD2 are consistently highly expressed across different
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!